Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...

The Lumipulse blood test identifies the presence of amyloid plaques, a hallmark of Alzheimer’s disease that impairs normal brain function.

FDA endorses first-of-its-kind blood test for Alzheimer’s disease The test is designed to detect amyloid plaques in the brain for patients with symptoms.

The lumipulse blood test brings renewed hope for earlier diagnosis and treatment for millions of people facing the uncertainty of Alzheimer's disease and other dementias.

The FDA has cleared Lumipulse, the first-ever blood test for early Alzheimer's detection, reducing the need for costly and invasive procedures.

The newly approved Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test marks a significant step forward in detecting indicators of Alzheimer’s with greater efficiency and accessibility.

The Lumipulse blood test identifies the presence of amyloid plaques, a hallmark of Alzheimer’s disease that impairs normal brain function.

The U.S. Food and Drug Administration cleared the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer’s disease. It’s got quite the name. The Lumipulse G pTau217 ...

Its mouthful of a name — Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio — describes what the test measures: levels of two proteins, amyloid and tau, that are hallmarks of Alzheimer’s disease.

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is approved for the early detection of amyloid plaques associated with Alzheimer disease in patients aged 55 years and older who are showing ...

Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of cognitive decline.